Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943
- 130 Downloads
To determine the maximum tolerated dose (MTD) and efficacy of pemetrexed and gemcitabine in patients with either biliary tract or gallbladder carcinoma.
Patients and Methods
Patients with unresectable previously untreated biliary tract cancers were eligible for participation. An initial phase I trial was performed to determine the MTD using an every-2-weeks schedule. The MTD was then used in the phase II portion of the trial. The primary end point for the phase II portion was 6-month survival with a planned accrual of 59 patients.
Overall, 63 eligible patients were enrolled. The MTD was established as pemetrexed 500 mg/m2 IV over 10 min and gemcitabine 800 mg/m2 IV at 10 mg/m2 per minute on days 1 and 15 of an every-4-weeks schedule with vitamin B12 and folate supplementation. Fifty-eight patients were included in the phase II portion. Median age was 61 and median follow-up was 18.2 months. A median of three cycles of treatment was given. Six-month survival was 55% and the median survival was 6.6 months (95% confidence interval 5.4–8.7 months) with a median time to progression of 3.8 months (2.4–5.4). Forty-seven (81%) experienced at least one grade 3+ adverse event, and 28 patients (48%) experienced at least one grade 4 adverse event, most of which were due to grade 4 neutropenia.
The addition of pemetrexed to fixed-dose-rate gemcitabine, in a biweekly schedule, did not enhance the activity of gemcitabine in patients with biliary tract or gallbladder carcinoma.
Keywordsbiliary tract cancer gallbladder cancer gemcitabine pemetrexed clinical trial
- 1.Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–9. doi: 10.1002/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X.PubMedCrossRefGoogle Scholar
- 8.Castro MP. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report [see comment]. Cancer. 1998;82:639–41. doi: 10.1002/(SICI)1097-0142(19980215)82:4<639::AID-CNCR4>3.0.CO;2-G.PubMedCrossRefGoogle Scholar
- 9.Gallardo J, Fodor M, Gamargo C, Orlandi L. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer. 1998;83:2419–21. doi: 10.1002/(SICI)1097-0142(19981201)83:11<2419::AID-CNCR23>3.0.CO;2-9.PubMedCrossRefGoogle Scholar
- 21.Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. doi: 10.1093/jnci/92.3.205.PubMedCrossRefGoogle Scholar
- 25.Cox DR. Regression models and life tables. J R Stat Soc (Series B). 1972;34:187–202.Google Scholar
- 31.Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) (Meeting abstract). J Clin Oncol. 2006;24:LBA.Google Scholar
- 32.Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer [erratum appears in Ann Oncol. 2006 Mar;17(3):535]. Ann Oncol. 2005;16:1639–45. doi: 10.1093/annonc/mdi309.PubMedCrossRefGoogle Scholar